Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 11, Issue 3, 2017, Pages 225-230

  Gupta, Ankit ^a   Jelinek, Herbert F ^b   Al Aubaidy, Hayder ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Dipeptidyl peptidase inhibitors; Glucagon like peptide 1; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; ANAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 2; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PROGLUCAGON; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TENELIGLIPTIN; TRELAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

BLOOD GLUCOSE MONITORING; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; INSULIN LIKE ACTIVITY; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; AGONISTS; AMINO ACID SEQUENCE; BLOOD; DISEASE MANAGEMENT; GENETICS; PHYSIOLOGY;

AMINO ACID SEQUENCE; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 85007017847     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2016.09.003     Document Type: Review

References (53)

1. Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132:6 (2007), 2131–2157.
2. McIntosh, C.H., Widenmaier, S., Kim, S.J., Two pleiotropic actions of the incretin hormones. Vitam Horm, 84, 2010, 21.
3. Barnett, A.H., O'Hare, P., Cardiovascular benefits of incretins. BMJ, 10(347 (Jul)), 2013, f4382.
4. Nauck, M.A., Baranov, O., Ritzel, R.A., et al. Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?. Diabetologia 56:9 (2013), 1878–1883.
5. Miyawaki, K., Yamada, Y., Yano, H., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci 96:26 (1999), 14843–14847.
6. Højberg, P.V., Vilsbøll, T., Rabøl, R., et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:2 (2009), 199–207.
7. Kjems, L.L., Holst, J.J., Vølund, A., et al. The influence of GLP-1 on glucose-stimulated insulin secretion effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:2 (2003), 380–386.
8. Muscelli, E., Mari, A., Casolaro, A., et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:5 (2008), 1340–1348.
9. Nauck, M.A., El-Ouaghlidi, A., Gabrys, B., et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 122:3 (2004), 209–217.
10. Knop, F.K., Aaboe, K., Vilsbøll, T., et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 14:6 (2012), 500–510.
11. Aaboe, K., Akram, S., Deacon, C.F., et al. Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors. Diabetes Obes Metab 17:1 (2015), 74–81.
12. Gault, V., Kerr, B., Harriott, P., et al. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clin Sci 121 (2011), 107–117.
13. Flatt, P.R., Bailey, C.J., et al. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr Drug Metab 10:2 (2009), 125–137.
14. Vollmer, K., Holst, J.J., Baller, B., et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:3 (2008), 678–687.
15. Myojo, S., Tsujikawa, T., Sasaki, M., et al. Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro. J Gastroenterol 32:3 (1997), 300–305.
16. Cheeseman, C.I., Tsang, R., The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport. Am J Physiol Gastrointest Liver Physiol 271 (1996), G477–G482.
17. Lovshin, J., Estall, J., Yusta, B., et al. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 276:24 (2001), 21489–21499.
18. Lovshin, J.A., Huang, Q., Seaberg, R., et al. Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology 145:7 (2004), 3495–3506.
19. Jeppesen, P.B., Hartmann, B., Thulesen, J., et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120:4 (2001), 806–815.
20. Wang, X., Cahill, C.M., Piñeyro, M.A., et al. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 140:10 (1999), 4904–4907.
21. Dupre, J., Ross, S.A., Watson, D., et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:5 (1973), 826–828.
22. Kreymann, B., Ghatei, M.A., Williams, G., et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 330:8571 (1987), 1300–1304.
23. Vilsbøll, T., Knop, F.K., Krarup, T., et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide—regardless of etiology and phenotype. J Clin Endocrinol Metab 88:10 (2003), 4897–4903.
24. Mentis, N., Vardarli, I., Köthe, L.D., et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60:4 (2011), 1270–1276.
25. Hopsu-Havu, V.K., Glenner, G.G., A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide. Histochem Cell Biol 7:3 (1966), 197–201.
26. Lambeir, A.M., Durinx, C., Scharpé, S., et al. Dipeptidyl-peptidase IV. from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:3 (2003), 209–294.
27. Filippatos Theodosios, D., Athyros, Vasilios G., Elisaf, Moses S., The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opin Drug Metab Toxicol 10:6 (2014), 787–812.
28. Bauvois, B., Djavaheri-Mergny, M., Rouillard, D., et al. Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells. Oncogene 19:2 (2000), 265–272.
29. Cordero, O.J., Salgado, F.J., Viñuela, J.E., et al. lnterleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology 197:5 (1997), 522–533.
30. Nielsen, L.L., Young, A.A., Parkes, D.G., Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117:2 (2004), 77–88.
31. Kolterman, O.G., Buse, J.B., Fineman, M.S., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:7 (2003), 3082–3089.
32. Kolterman, O.G., Kim, D.D., Shen, L., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 62:2 (2005), 173–181.
33. Szayna, M., Doyle, M.E., Betkey, J.A., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:6 (2000), 1936–1941.
34. Xu, G., Stoffers, D.A., Habener, J.F., et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:12 (1999), 2270–2276.
35. Bunck, M.C., Diamant, M., Cornér, A., et al. One-year treatment with exenatide improves (-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients a randomized, controlled trial. Diabetes Care 32:5 (2009), 762–768.
36. Kendall, D.M., Riddle, M.C., Rosenstock, J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes care 28:5 (2005), 1083–1091.
37. Klonoff, D.C., Buse, J.B., Nielsen, L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years*. Curr Med Res Opin 24:1 (2007), 275–286.
38. Seino, Y., Min, K.W., Niemoeller, E., et al. Randomized, double‐blind, placebo‐controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal‐L‐Asia). Diabetes Obes Metab 14:10 (2012), 910–917.
39. Vilsbøll, T., Liraglutide a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 16:2 (Feb) (2007), 231–237.
40. Russell-Jones, D., Vaag, A., Schmitz, O., et al. Liraglutide effect and action in diabetes 5 (LEAD-5) met+ SU study group: liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomised controlled trial. Diabetologia 52:10 (2009), 2046–2055.
41. Vilsbøll, T., Brock, B., Perrild, H., et al. Liraglutide, a once‐daily human GLP‐1 analogue, improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 25:2 (2008), 152–156.
42. Buse, J.B., Rosenstock, J., Sesti, G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:9683 (2009), 39–47.
43. Trujillo, J.M., Nuffer, W., Albiglutide a new glp-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother 48:11 (2014), 1494–1501.
44. Lindamood, C.A., Taylor, J.R., Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists. Clin Ther 37:3 (2015), 483–493.
45. Wysham, C., Blevins, T., Arakaki, R., et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 37:8 (2014), 2159–2167.
46. Baetta, R., Corsini, A., Pharmacology of dipeptidyl peptidase-4 inhibitors. Drugs 71:11 (2011), 1441–1467.
47. Nabeno, M., Akahoshi, F., Kishida, H., et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biophys Res Commun 434:2 (2013), 191–196.
48. Nauck, M.A., Kleine, N., Ørskov, C., et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:8 (1993), 741–744.
49. Nauck, M.A., Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124:1 (2011), S3–18.
50. Nauck, M.A., Baranov, O., Ritzel, R.A., et al. Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?. Diabetologia 56:9 (2013), 1878–1883.
51. Madsbad, S., Holst, J.J., GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgery. Diabetes 63:10 (2014), 3172–3174.
52. Finan, B., Yang, B., Ottaway, N., et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:1 (Jan) (2015), 27–36.
53. Nauck, M.A., Vilsbøll, T., Gallwitz, B., Garber, A., Madsbad, S., Incretin-based therapies viewpoints on the way to consensus. Diabetes Care 32:Suppl. 2 (2009), S223–S231.